Oruka amends IL-23 license agreement with Paragon expanding field to all therapeutic areas
Oruka Therapeutics and Paragon Therapeutics executed a first amendment to their IL-23 license agreement dated May 29, 2026, expanding the Field definition from inflammatory bowel disease to all therapeutic areas. The amendment broadens Oruka's development rights and commercial opportunities for IL-23 targeted therapeutics across multiple indications.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day